Insider John Mack Buys Shares of Orchestra BioMed Holdings
John Mack purchased 34,653 shares of Orchestra BioMed Holdings, Inc. on June 23, 2026.
Key Points
- John Mack acquired 34,653 shares of Orchestra BioMed Holdings on June 23, 2026, as an insider transaction.
- Orchestra BioMed Holdings, Inc. has a market cap of approximately $233.5 million and traded at $3.98 on Friday.
- Analysts from firms like Barclays and B. Riley Securities maintain a 'buy' rating with price targets ranging from $10 to $20.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, John Mack, an insider at Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO), purchased 34,653 shares of the company. This transaction, coded as "A" for acquisition, did not specify a price or total value. The stock traded at $3.98 on Friday.
Other Institutional Activity in Orchestra BioMed Holdings
RTW Investments, LP held its position steady with 8,306,063 shares valued at about $35.3 million. Perceptive Advisors LLC trimmed its holdings by 89,350 shares, bringing its total to 5,037,906 shares, worth approximately $21.4 million, reflecting a 1.7% decrease. Vanguard Capital Management LLC opened a new position with 2,204,319 shares valued at roughly $9.4 million. Propel Bio Management, LLC also initiated a stake, acquiring 896,701 shares worth about $3.8 million. Meanwhile, Millennium Management LLC increased its stake by 459,070 shares, now holding 702,543 shares valued at $2.99 million, marking a 188.6% increase.
Orchestra BioMed Holdings, Inc. Stock Down 24.8%
Shares of Orchestra BioMed Holdings, Inc. traded near $3.98 on Friday. The company has a market capitalization of approximately $233.5 million. While it currently has no meaningful P/E ratio due to lack of profitability, it has a forward P/E of -2.67. The stock's beta is 0.5, indicating lower volatility compared to the market. Its 52-week range is between $2.20 and $5.42, with a 50-day moving average of $4.03 and a 200-day moving average of $3.99. The company's current ratio is 7.03, and its quick ratio is 6.90, with a debt-to-equity ratio of 31.10.
$OBIO stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent earnings report, Orchestra BioMed Holdings, Inc. recorded revenue of $32.7 million, though it experienced a revenue decline of 87.3% year-over-year. The company posted a net margin of -166.96% and a return on equity of -161.12%. The next earnings report is scheduled for May 12, 2026.
Insider Buying and Selling at Orchestra BioMed Holdings, Inc.
On June 23, 2026, besides John Mack's purchase, Eric Fain bought 17,327 shares as well. On June 24, 2026, several insiders, including Chris Cleary, John Mack, and Eric Fain, sold shares, with transactions not part of a pre-planned 10b5-1 trading plan.
Analysts Set New Price Targets
Analysts remain optimistic about Orchestra BioMed Holdings. On May 19, 2026, B. Riley Securities maintained its 'buy' rating with a $10 price target. Similarly, HC Wainwright & Co. reiterated a 'buy' rating with the same target on May 14, 2026. Barclays has maintained a 'buy' rating with a target of $13 as of May 13, 2026. The consensus rating is a 'buy', with an average price target of $12.17 based on six analyst opinions.
About Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. is a healthcare company based in New Hope, Pennsylvania. It focuses on developing innovative biomedical therapies. Its key products include Atrioventricular Interval Modulation for blood pressure management and Virtue Sirolimus AngioInfusion Balloon for artery disease treatment. The company collaborates with Medtronic and Terumo for product development and commercialization. Founded in 2018, it is led by CEO David P. Hochman and employs 86 people.
Bottom Line
John Mack's insider purchase of Orchestra BioMed Holdings shares highlights investor interest in the company. While the company faces challenges with profitability, it remains a focus for institutional investors, as seen in recent fund activity. Analysts maintain a positive outlook, with several firms issuing 'buy' ratings and setting price targets significantly above current levels. Remember, insider and institutional transactions are backward-looking and don't necessarily reflect current positions.
Get Orchestra BioMed Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.